Related Experiment Videos
Control of the classical and the MBL pathway of complement activation
S V Petersen1, S Thiel, L Jensen
1Department of Medical Microbiology and Immunology, The Bartholin Building, University of Aarhus, DK-8000, Aarhus, Denmark. svp@microbiology.au.dk
Molecular Immunology
|March 21, 2001
Summary
Researchers explored inhibitors for the mannan-binding lectin (MBL) pathway of complement activation. They found specific synthetic inhibitors that differ from those targeting the classical pathway, suggesting targeted MBL inhibition is possible.
Area of Science:
- Immunology
- Biochemistry
Background:
- The mannan-binding lectin (MBL) pathway initiates complement activation via the MBL complex, comprising MBL, MASP-1, MASP-2, and MAp19.
- MBL deficiency is associated with infections and miscarriage, while uncontrolled complement activation causes chronic diseases.
Purpose of the Study:
- To identify biological and synthetic inhibitors of the MBL pathway.
- To compare the inhibitory profiles of the MBL pathway with the classical complement pathway.
Main Methods:
- Utilized a specific assay to measure MBL complex complement activation.
- Compared inhibitor activity against MBL, C1 complex, and MBL-MASP-2 complexes.
- Assessed inhibitor and component dissociation from the MBL complex under varying ionic strengths.
Main Results:
- Synthetic inhibitors showed differential activity against MBL and classical pathways.
- C1 inhibitor affected both pathways, while alpha2-macroglobulin (alpha2M) affected neither.
- MBL complex components and associated inhibitors dissociated in physiological buffer but not in high ionic strength buffer.
Conclusions:
- The MBL pathway's activation and control mechanisms differ from the classical pathway.
- These findings suggest the potential for specific inhibition of the MBL pathway.
- Targeted MBL pathway inhibition could offer therapeutic strategies for complement-mediated diseases.